The Global Pharmaceutical-grade HFA-134a Market was valued at USD 752 Million in 2025 and is projected to reach USD 1,242 Million by 2034, growing at a Compound Annual Growth Rate (CAGR) of 7.7% during the forecast period (2026-2034). This growth is driven by increasing respiratory disease prevalence, the global phase-out of CFC propellants, and stringent pharmacopoeial standards for inhalation therapies.

Pharmaceutical-grade HFA-134a (1,1,1,2-tetrafluoroethane) has become the global standard propellant for metered-dose inhalers (MDIs) used in treating asthma and COPD. As the industry focuses on drug delivery innovation and regulatory compliance, we profile the Top 10 Companies in the Pharmaceutical-grade HFA-134a Market—specialty chemical manufacturers and fluorocarbon producers ensuring safe, high-purity propellant supply for respiratory medicines.

---

🔟 1. SRF Limited

Headquarters: Gurugram, India
Key Offering: HFA-134a (99.99% purity), Pharmaceutical Propellant Solutions

SRF is a leading global producer of fluorochemicals and the dominant supplier of pharmaceutical-grade HFA-134a. The company operates dedicated GMP-compliant production lines that meet USP/EP standards, supplying major inhaler manufacturers worldwide.

Quality Initiatives:

• USD 50M investment in high-purity HFA-134a capacity expansion (2023)
• FDA-approved manufacturing facilities with ≤10ppb impurity levels
• Strategic contracts with top 5 global pharmaceutical companies

Download FREE Sample Report: Pharmaceutical-grade HFA-134a Market – View in Detailed Research Report

---

9️⃣ 2. Koura Global

Headquarters: Manchester, United Kingdom
Key Offering: Zephex® HFA-134a (Medical Grade), Propellant Blending Services

A division of Mexichem, Koura is Europe’s premier pharmaceutical propellant supplier with over 30 years of experience. Their Zephex® line sets industry benchmarks for consistency and ultra-low non-volatile residue content.

Notable Achievements:

• Supplies 60% of European MDI manufacturers
• Proprietary purification technology achieving 99.997% purity
• Pioneer in next-gen low-GWP propellant research

---

8️⃣ 3. Zhejiang Juhua Co., Ltd.

Headquarters: Quzhou, China
Key Offering: Juhua-HFA (Medical Grade), Propellant Packaging Solutions

As China’s largest fluorochemical producer, Juhua controls 40% of the Asian pharmaceutical HFA-134a market. The company benefits from vertical integration and government support in respiratory drug manufacturing.

Recent Developments:

• New 10,000-ton/year medical-grade production line (2025)
• WHO prequalified for global health organization supply
• Strategic partnerships with Asian generic inhaler manufacturers

---

7️⃣ 4. Honeywell International Inc.

Headquarters: Charlotte, North Carolina, USA
Key Offering: Solstice® Air HFA-134a, Propellant Formulation Expertise

Honeywell’s performance materials division produces ultra-high purity HFA-134a for leading respiratory drug companies. Their proprietary Solstice® technology platform addresses both performance and environmental concerns.

Environmental Focus:

• 98% reduction in production emissions since 2018
• First to develop GWP-reduced HFA blends (patent pending)
• FDA master file holder for multiple approved MDI products

Download FREE Sample Report: Pharmaceutical-grade HFA-134a Market – View in Detailed Research Report

---

6️⃣ 5. Arkema S.A.

Headquarters: Colombes, France
Key Offering: Forane® HFA-134a, Custom Propellant Blends

Arkema’s fluorine specialties division serves the European pharmaceutical market with consistent, high-performance propellant solutions. The company holds multiple patents for stabilizing sensitive drug formulations.

Technical Capabilities:

• Class 100,000 clean room packaging facilities
• Moisture control to ≤10ppm water content
• Just-in-time delivery to 30+ EU pharmaceutical sites

---

5️⃣ 6. Daikin Industries

Headquarters: Osaka, Japan
Key Offering: Daiflon® HFA-134a, Inhalation-Grade Propellant

Daikin combines Japanese precision engineering with global supply capabilities. The company leads in APAC with pharmaceutical-grade production facilities in Japan, China, and India serving regional MDI makers.

Quality Standards:

• JP18/EP10.0/USP-NF compliance verified
• Automated impurity detection systems (0.5ppm sensitivity)
• Dedicated pharma supply chain with triple-redundancy

---

4️⃣ 7. Dongyue Group

Headquarters: Zibo, China
Key Offering: DY-HFA Medical Grade, Cost-Competitive Propellants

This Chinese fluorochemical leader has rapidly expanded into pharmaceutical propellants, offering competitively priced HFA-134a while maintaining pharmacopoeial standards. Dongyue supplies 25% of China’s domestic MDI market.

Market Position:

• 200% production capacity increase since 2021
• Strategic focus on emerging market accessibility
• GMP+ certification for European market entry

---

3️⃣ 8. Navin Fluorine International

Headquarters: Mumbai, India
Key Offering: NFI-Medical HFA, Propellant-Drug Compatibility Services

Navin Fluorine combines propellant manufacturing with formulation expertise, serving both multinationals and Indian generic drug companies. The company specializes in complex drug-propellant systems.

Value-Added Services:

• In-house analytical method development
• Drug-propellant interaction studies
• Regulatory support for ANDA submissions

Download FREE Sample Report: Pharmaceutical-grade HFA-134a Market – View in Detailed Research Report

---

2️⃣ 9. Chemours Company

Headquarters: Wilmington, Delaware, USA
Key Offering: Vertrel® HFA-134a, Specialty Fluids Solutions

Chemours brings decades of fluorochemical expertise to the pharmaceutical propellant market. Their Vertrel® line serves both respiratory and topical spray applications with exceptional lot-to-lot consistency.

Technical Leadership:

• Pioneer in fluorocarbon purification technologies
• Proprietary contaminant removal processes
• FDA Drug Master Files for multiple propellant grades

---

1️⃣ 10. Yingpeng Chemicals

Headquarters: Taizhou, China
Key Offering: YP-Med HFA134a, Budget Medical Propellant

Yingpeng has emerged as a cost leader in pharmaceutical-grade HFA-134a, supplying Chinese and Southeast Asian markets. The company balances affordability with strict impurity controls for essential medicines.

Growth Strategy:

• Strategic partnerships with generic drug manufacturers
• Focus on WHO essential medicine compliance
• 30% year-on-year capacity expansion

---

🌬️ Outlook: The Future of Pharmaceutical Propellants

The pharmaceutical HFA-134a market is evolving to meet therapeutic needs while addressing environmental concerns. With the MDI market projected to grow at 5.8% CAGR through 2030, propellant manufacturers are innovating to ensure supply security and sustainability.

📈 Key Market Trends:

• Shift to ≥99.99% purity standards for next-gen formulations
• Development of low-GWP propellant alternatives
• Supply chain localization for regional security
• Digitization of quality control systems

Get Full Report Here: Pharmaceutical-grade HFA-134a Market – View in Detailed Research Report

These top companies are not just supplying propellants—they’re enabling critical respiratory therapies for millions of patients worldwide.